Aisa Pharma Announces Encouraging Results from Phase 2 RECONNOITER Trial of AISA-021 (Cilnidipine) in Patients with Systemic Sclerosis-Associated Raynaud's Phenomenon

Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...
Knowridge Science Report

Common blood pressure pills may quietly raise risk of vision loss

Millions of people around the world take medicine every day to control high blood pressure. These medicines help protect the heart, brain, and blood vessels from serious problems such as heart attacks ...
Healio

‘Rather disappointing’: Ethosuximide fails in IBS-related pain despite analgesic benefit

Ethosuximide, a T-type calcium channel blocker, demonstrated no significant benefit as a treatment for patients with ...
Open Heart

Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...